EA201892524A1 - Днк-моноклональные антитела, нацеленные на il-6 и cd126 - Google Patents

Днк-моноклональные антитела, нацеленные на il-6 и cd126

Info

Publication number
EA201892524A1
EA201892524A1 EA201892524A EA201892524A EA201892524A1 EA 201892524 A1 EA201892524 A1 EA 201892524A1 EA 201892524 A EA201892524 A EA 201892524A EA 201892524 A EA201892524 A EA 201892524A EA 201892524 A1 EA201892524 A1 EA 201892524A1
Authority
EA
Eurasian Patent Office
Prior art keywords
monoclonal antibodies
antibodies targeted
dna monoclonal
composition
dna
Prior art date
Application number
EA201892524A
Other languages
English (en)
Inventor
Дэвид Уэйнер
Сара Эллиотт
Original Assignee
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания, Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи filed Critical Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Publication of EA201892524A1 publication Critical patent/EA201892524A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В настоящем описании раскрыта композиция, включающая в себя рекомбинантную последовательность нуклеиновой кислоты, которая кодирует синтетическое антитело к IL-6 и/или к CD126. В настоящем описании также раскрыт способ предотвращения и/или лечения у субъекта заболевания с использованием указанной композиции и способ ее создания.
EA201892524A 2016-05-05 2017-05-05 Днк-моноклональные антитела, нацеленные на il-6 и cd126 EA201892524A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05
PCT/US2017/031193 WO2017192933A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Publications (1)

Publication Number Publication Date
EA201892524A1 true EA201892524A1 (ru) 2019-04-30

Family

ID=60203626

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892524A EA201892524A1 (ru) 2016-05-05 2017-05-05 Днк-моноклональные антитела, нацеленные на il-6 и cd126

Country Status (12)

Country Link
US (1) US20190192692A1 (ru)
EP (1) EP3452106A4 (ru)
JP (2) JP7311113B2 (ru)
KR (2) KR20190031439A (ru)
CN (1) CN109789224A (ru)
AU (2) AU2017261292B2 (ru)
BR (1) BR112018072697A2 (ru)
CA (1) CA3023089A1 (ru)
EA (1) EA201892524A1 (ru)
MX (1) MX2018013523A (ru)
SG (2) SG11201809786TA (ru)
WO (1) WO2017192933A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体
KR102635888B1 (ko) 2019-03-19 2024-02-15 엘지전자 주식회사 공기청정기
EP4277929A1 (en) * 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1562968T3 (da) * 2001-11-14 2013-10-28 Janssen Biotech Inc Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser
PL1960430T3 (pl) 2005-12-09 2015-03-31 Ucb Pharma Sa Cząsteczki przeciwciał wykazujące swoistość dla ludzkiej il-6
MX2009001110A (es) * 2006-08-03 2009-05-11 Vaccinex Inc Anticuerpos monoclonales anti-il-6 y usos de los mismos.
US8034344B2 (en) 2008-05-13 2011-10-11 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
BR112015013700A8 (pt) * 2012-12-13 2020-02-18 Inovio Pharmaceuticals Inc composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
US9925263B2 (en) 2013-09-11 2018-03-27 Eagle Biologics, Inc. Liquid pharmaceutical formulations for injection comprising procaine and uses thereof

Also Published As

Publication number Publication date
AU2017261292B2 (en) 2024-06-06
JP7311113B2 (ja) 2023-07-19
AU2024203109A1 (en) 2024-05-30
SG10202011023YA (en) 2020-12-30
EP3452106A1 (en) 2019-03-13
AU2017261292A1 (en) 2018-12-20
CA3023089A1 (en) 2017-11-09
EP3452106A4 (en) 2020-01-08
JP2019518074A (ja) 2019-06-27
JP2023086734A (ja) 2023-06-22
MX2018013523A (es) 2019-06-10
KR20190031439A (ko) 2019-03-26
WO2017192933A1 (en) 2017-11-09
US20190192692A1 (en) 2019-06-27
CN109789224A (zh) 2019-05-21
SG11201809786TA (en) 2018-12-28
KR20230058733A (ko) 2023-05-03
BR112018072697A2 (pt) 2019-02-19

Similar Documents

Publication Publication Date Title
EA201892522A1 (ru) Днк-моноклональные антитела, нацеленные на молекулы контрольных точек
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201890874A1 (ru) Антитела, которые эффективно нейтрализуют вирус гепатита в, и их применение
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
EA201892793A1 (ru) Анти-hla-g специфические антитела
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201891165A1 (ru) Молекулы, связывающие pd1 и/или lag3
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201992091A1 (ru) Анти-c5 антитела и их применение
PE20150023A1 (es) Proteinas de union a antigeno st2
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201791984A1 (ru) Способы уменьшения уровня fc-содержащих агентов в сыворотке с применением fcrn-антагонистов
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
PE20190208A1 (es) Anticuerpos que reconocen tau
EA201592285A1 (ru) Антигенсвязывающие белки к рецептору онкостатина м
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья